´â¼­Åµ
  ÏÀʸ°ìÍ÷¡¡Ê¬³äɽ¼¨¡¡5¡¿10
´Ê°×¸¡º÷
¡¡   
¡¡
¥ê¥¹¥È¹¹¿·¡§2008/03/01(Sat) 05:13 JST
¹¹¿·¤Ï½ªÎ»¤·¤Þ¤·¤¿ ºÇ¿·¤Ï ʬ³äɽ¼¨¡¡1¡¿10

£±ÊÇɽ¼¨¤Ï¡¡¤³¤Á¤é¡£¡¡¡¡¡¡ ¤³¤Á¤é¤â¡¡ÊIJͽñ¸Ë¡¦¥ê¥¹¥È°ìÍ÷


¼ýÏ¿ÏÀʸ¡¡Á´[3889]·ïÃæ¡¡¥¢¥ë¥Õ¥¡¥Ù¥Ã¥È½ç[400]·ï

1¡¿10¤Ø¡¡ 2¡¿10¤Ø¡¡ 3¡¿10¤Ø¡¡ 4¡¿10¤Ø¡¡ 5¡¿10¡¡ 6¡¿10¤Ø¡¡ 7¡¿10¤Ø¡¡ 8¡¿10¤Ø¡¡ 9¡¿10¤Ø¡¡ 10¡¿10¤Ø¡¡
¡¡
¡¡ÏÀʸ̾¶èʬ
TS-1¿·µ¬ÅêͿˡ¤òÍѤ¤¤¿½ÑÁ°²½³ØÎÅË¡¤Ë¤è¤êCR¤È¤Ê¤Ã¤¿¸ý¿°´â¤Î1Îã ¢¡²½³ØÎÅË¡ ¾
TS-1ÂÑÀ­ºÆÈ¯°ß´â¤ËÂФ·¤ÆTS-1+DocetaxelÎÅË¡¤¬ÁÕ¸ú¤·¤¿1Îã ¢¡°ß´â ¾
TS-1ñÆÈ¤È¾ºÞ¤È¤ÎÊ»ÍÑÎÅË¡¤Î·Ñ³¤Ë¤è¤ê5ǯÀ¸Â¸¤òÆÀ¤¿Ê¢ËìÇżïÍÛÀ­°ß´â¤Î1Îã ¢¡´âÀ­Ê¢Ëì±ê ¾
TS-1ñÆÈÅêÍ¿¤Ë¤Æ4ǯ´ÖÀ¸Â¸Ãæ¤ÎStageIV¿Ê¹Ô°ß´â¤Î1Îã ¢¡£··îÂ裵½µ¡§£³£±Æü¡ÊÆü¡Ë ¾
TS-1ñÆÈÅêÍ¿¸å¤ËTS-1¡¦CDDP¾¯ÎÌÏ¢ÆüÊ»ÍÑÎÅË¡¤Ë¤è¤ê¼ê½Ñ¤¬²Äǽ¤È¤Ê¤Ã¤¿ºÆÈ¯°ß´â¤Î1Îã ¢¡°ß´â ¾
TS-1ñÆÈÆâÉþÎÅË¡¤Ë¤è¤êÌó3ǯ´Ö¤ÎĹ´ü´Ë²ò¤òÆÀ¤¿¥¹¥­¥ë¥¹°ß´â¤È¹Í¤¨¤é¤ì¤ë1Îã ¢¡¥¹¥­¥ë¥¹ ¾
TS-1ÄãÍÑÎÌCDDPÎÅË¡¤Ë¤è¤êĹ´üÀ¸Â¸¤òÆÀ¤Æ¤¤¤ëºÆÈ¯°ß´â¤Î2¾ÉÎã ¢¡°ß´â ¾
TS-1Äñ¹³À­¤È¤Ê¤Ã¤¿ÀÚ½üÉÔǽ¿Ê¹Ô°ß´â¤ËÂФ·¤ÆPaclitaxel+DoxifluridineÊ»ÍÑÎÅË¡¤¬Ãø¸ú¤·¤¿1Îã ¢¡Å¾°ÜÀ­´Î¡´â ¾
TS-1Äñ¹³À­ºÆÈ¯°ß´â¤ËÂФ¹¤ë²½³ØÊü¼ÍÀþ¼£ÎŤηи³ ¢¡°ß´â ¾
TS-1ÅêÍ¿¤¬ÁÕ¸ú¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã¡¡¡¦¡¦¡¦¤Ï¤¸¤á¤Ë¡¡¡¡ ­µ.¾ÉÎã¡¡73ºÐ¡¡½÷À­¡¡¿©»×ÉÔ¿¶¡¡34¥ö·îºÆÈ¯Ãû¸õǧ¤á¤Ê¤¤¡¡¡¡Borrm¡¦¡¦ ¢¡°ß´â ¾
TS-1ÅêÍ¿¤¬Ãø¸ú¤·¤¿°ß´â½Ñ¸å´Îž°Ü¤Î1Îã ¢¡°ß´â ¾
TS-1ÅêÍ¿¤Ç´Îž°Ü¤¬CR¤È¤Ê¤Ã¤¿Ê¢ËìÇżï¤ÎÃøÌÀ¤ÊÀÚ½üÉÔǽ¤ÎS¾õ·ëIJ´â¤Î1Îã ¢¡·ëIJ´â ¾
TS-1ÅêÍ¿¤Ë¤è¤êCR¤¬ÆÀ¤é¤ì¤¿Â¿È¯À­´Îž°Ü¤òȼ¤¦°ß´â¤Î1Îã ¢¡°ß´â ¾
TS-1ÅêÍ¿¤Ë¤è¤êQOL²þÁ±¤òǧ¤á¤¿¿Ê¹Ô°ß´É´â¤Î1Îã ¢¡°ß´â ¾
TS-1ÅêÍ¿¤Ë¤è¤êÃø¸ú¤¬ÆÀ¤é¤ì¤¿Ê¢ÉôÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀáž°Ü¡¤ðôÄÇž°Ü¡¤Ê¢ËìÇżïž°Ü¤òÍ­¤·¤¿¿Ê¹ÔÂçIJ´â¤Î1Îã ¢¡´âÀ­Ê¢Ëì±ê ¾
TS-1ÅêÍ¿¤Ë¤è¤êÌó9¤«·î¤ÎNC(No Change)¾õÂÖ¤ò°Ý»ý¤Ç¤­¤¿±ó³Öž°Ü¤òÍ­¤¹¤ë¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
TS-1ÅêÍ¿¤Ë¤è¤êÎɹ¥¤ÊQOL(Quality of Life)¤¬Ä¹´ü´Ö°Ý»ý¤µ¤ì¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
TS-1ÅêÍ¿¸åÁá´ü¤ËHand-Foot Syndrome¤¬È¯¾É¤·¤¿ºÆÈ¯°ß´â¤Î1Îã ¢¡°ß´â ¾
TS-1ÆâÉþ¤ÈÊü¼ÍÀþ¾È¼ÍÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿T4²¼³Ü»õÆù´â¤Î1Îã30-09
TS-1ȾÎÌÅêÍ¿¤Ë¤è¤ê°ä»ÄÉÂÊѤ¬¾Ã¼º¤·¤¿¿©Æ»¿»½á¤òȼ¤¦»Ä°ß´â¤Î1Îã ¢¡¿©Æ»´â ¾
TS-1ÉÔ±þ¿Ê¹ÔºÆÈ¯°ß´â¤ËÂФ¹¤ëSecond-Line Chemotherapy¤È¤·¤Æ¤ÎPaclitaxel WeeklyÅêÍ¿ ¢¡°ß´â ¾
TS-1ÎÅË¡¤¬Ãø¸ú¤·¤¿Áá´ü°ß´âÀÚ½ü8ǯ¸å¤Î¿ȯÀ­¹üž°Ü¤Î1Îã ¢¡£··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾
TS-1ÎÅË¡¸å¤ÎSecond-Line Chemotherapy¤È¤·¤Æ¤ÎLow-Dose PaclitaxelÎÅË¡¤Î·Ð¸³ ¢¡°ß´â ¾
TS/DPD³èÀ­¤ÎÂçIJ´â¤ËÂФ¹¤ëUFT¤Î¸ú²Ìͽ¬°ø»Ò¤È¤·¤Æ¤Î°ÕµÁ ¢¡ÂçIJ´â ¾
TS¡¦DPDmRNAȯ¸½¤«¤é¤ß¤¿TS-1ñºÞÎÅË¡¤ÈTS-1+CPT-11Ê»ÍÑÎÅË¡¤Î°ÌÃÖÉÕ¤± ¢¡°ß´â ¾
TS¡¾1¤ËÂФ¹¤ë¥¢¥ì¥ë¥®¡¼»î¸³¤È¤·¤Æ¤Î¥ê¥ó¥Ñµå»É·ã»î¸³(DLST)¤Î°ÕµÁ ¢¡²½³ØÎÅË¡ ¾
Tumor dormancy¤òÌÜŪ¤È¤·¤¿ÀÚ½üÉÔǽ¿Ê¹Ôç¹´â¤ËÂФ¹¤ë²¹Ç®²½³ØÎÅË¡¤ÎŬ±þ ¢¡21-Supplement ­¶ ¾
Two-step interferon rebound therapy ¢¡´Î±ê ¾
TXT¡¦CDDP¡¦5-FUÊ»ÍÑÎÅË¡¤¬¼ª²¼Á£´â´Îž°ÜÁã¤ËÁÕ¸ú¤·¤¿1Îã ¢¡ÂñÕÁ£´â ¼ª²¼Á£´â¡¡ ¾
TʬÎà¤òÍѤ¤¤¿Æý˼²¹Â¸½Ñ¸å¤ÎÆý˼ºÆÈ¯Îã¤Î¸¡Æ¤ ¢¡£¸·î£±Æü ¾
Ubenimex¤Ë¤è¤ê½Ñ¸å5ǯ´Ö´²²ò¤¬ÆÀ¤é¤ì¤Æ¤¤¤ë¿ÕºÙ˦´â¥ê¥ó¥ÑÀឰܤÎ1Îã ¢¡¿Õ¡´â ¾
UC´ØÏ¢À­ÂçIJ´â¤ÎÁá´ü¿ÇÃÇ-¥µ¡¼¥Ù¥¤¥é¥ó¥¹¤Î¸½¶·¤ÈŸ˾¡½ ¢¡£±£°·î£±Æü£Õ£Ð ¾
UFT+LeucovorinÎÅË¡¤¬Ãø¸ú¤·¤¿ºÆÈ¯·ëIJ´â¤Î1Îã ¢¡·ëIJ´â ¾
UFT,Cyclophosphamide,Medroxyprogesterone AcetateÎÅË¡¤¬Ãø¸ú¤ò¼¨¤·¤¿Anthracycline,TaxaneÂÑÀ­Æý´â¿ȯ´Îž°Ü¤Î1Îã ¢¡£··îÂ裴½µ¡§£²£´Æü¡ÊÆü¡Ë ¾
UFT/Leucovorin·Ð¸ýÆâÉþÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿S¾õ·ëIJ´â¿ȯÇÙž°Ü¤Î1Îã ¢¡ÇÙ´â ¾
 ¢¡3925ÂçIJ´â ¾
UFT¤¬ÁÕ¸ú¤·¥é¥¸¥ªÇȾƼ޽Ѥò»Ü¹Ô¤·ÆÀ¤¿µðÂç´ÎºÙ˦´â¤Î1Îã ¢¡´Î¡´â ¾
UFT¤¬Ãø¸ú¤·¤¿ÍñÁãÈéÍÍǹ¼ð¤Î°­À­Å¾²½¤È»ÒµÜÆâËìÁ£´â¤ÎƱ»þÀ­½ÅÊ£´â¤Î1Îã ¢¡£²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾
UFT¤ÎÂå¼Õʪ¤Ç¤¢¤ëGHB¤Î·ì´É¿·À¸Á˳²¸ú²Ì¤È¹³¼ðáç¸ú²Ì ¢¡²½³ØÎÅË¡ ¾
UFT·Ð¸ý¤ª¤è¤Ó5-FU´Ö·çŪ´ÎưÃíÎÅË¡¤¬Ãø¸ú¤·¤¿°ß´âƱ»þÀ­´Îž°Ü¤Î1Îã ¢¡°ß´â ¾
UFT·Ð¸ýÅêÍ¿¤¬Ãø¸ú¤·¤¿´ÎºÙ˦´â¤ÎÊ¢¹ÐÆâ¥ê¥ó¥ÑÀឰܤÎ1Îã ¢¡´Î¡´â ¾
UFT·Ð¸ýÅêÍ¿¤¬Ãø¸ú¤·¤¿¹âÎð¼Ô¿ȯ´Îž°Ü¹çÊ»¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
UFTñºÞÎÅË¡¤¬Ãø¸ú¤·¤¿ÃÀǹ´â½Ñ¸åÂçÆ°Ì®¥ê¥ó¥ÑÀáºÆÈ¯¤Î1Îã ¢¡ÃÀÆ»´â ¾
UFTñÆÈÎÅË¡¤¬ÁÕ¸ú¤·¤¿µðÂç¤Ê³Ü²¼Éô°­À­¼ðáç¤Î1Îã ¢¡¾å³Ü´â ¾
UFTÄɲäˤè¤êGemcitabine¡ÜVinorelbineÊ»ÍÑÎÅË¡¤¬ºÆÅÙÍ­¸ú¤Ë¤Ê¤Ã¤¿´âÀ­¶»¿å¤Î1Îã ¢¡¶»Éô ¾
UFTÊ»ÍÑGemcitabine²½³ØÎÅË¡¸å¿Ê¹Ô¤·¤¿½Ñ¸åºÆÈ¯À­ç¹´â¤ËÂФ·TS-1Ê»ÍÑGemcitabine²½³ØÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿1Îã33-06
UIPÉÂÊÑ¡ÊUsual Interstitial Pneumonia Pattern/Lesion¡Ë¤òÍ­¤¹¤ë¸ÄÂΤǤνѸåµÞÀ­Áý°­ ¢¡£±£°·î£±Æü£Õ£Ð ¾
VEGFR¤ÈEGFR¥Á¥í¥·¥ó¥­¥Ê¡¼¥¼¤ÎξÊý¤òɸŪ¤È¤¹¤ëÁªÂòŪÁ˳²ºÞ ZD6474¤Ë¤Ä¤¤¤Æ ¢¡²½³ØÎÅË¡ ¾
Vinorelbine ¡Ý¤³¤ì¤«¤é¤ÎÆý´â¼£ÎÅÌô ¢¡8·îÂ裴½µ¡¡£²£¶Æü ¾
Vinorelbine+Cisplatin¤ÈÊü¼ÍÀþ¤ÎƱ»þÊ»ÍÑÎÅË¡¤¬Ãø¸ú¤·¤¿½Ñ¸å½Ä³ÖºÆÈ¯ÇÙ´â¤Î2Îã ¢¡ÇÙ´â ¾
Vinorelbine¡¤CarboplatinÊ»ÍÑÎÅË¡¤Ë¤è¤ê¼ðáç½Ì¾®¤òǧ¤áĹ´ü³°Íè·Ñ³ÅêÍ¿¤¬²Äǽ¤Ç¤¢¤Ã¤¿¿Ê¹ÔÈ󾮺Ù˦ÇÙ´â¤Î1Îã ¢¡È󾮺Ù˦´â ¾
Vinorelbine¡¤GemcitabineÊ»ÍÑÎÅË¡¤¬Ãø¸ú¤·¤¿PSÎɹ¥¤Ê¹âÎð¼Ô¤Î¿Ê¹ÔÈ󾮺Ù˦ÇÙ´â¤Î1Îã ¢¡È󾮺Ù˦´â ¾
Vinorelbine¤È¥×¥é¥Á¥ÊÀ½ºÞ¤¬ÁÕ¸ú¤·CR¤òÆÀ¤é¤ì¤¿ºÆÈ¯ÇÙ´â¤Î1Îã ¢¡ÇÙ´â ¾
Vinorelbine¤Ë¤è¤ë³°Íè¼£ÎŤ¬Í­¸ú¤Ç¤¢¤Ã¤¿½Ñ¸åºÆÈ¯ÇÙ´â¤Î1Îã ¢¡ÇÙ´â ¾
Virchowž°Ü¤òȼ¤Ã¤¿¾®Ä²´â¤ËÂФ·TS-1ÎÅË¡¤¬ÁÕ¸ú¤·¤¿1Îã ¢¡·ëIJ´â ¾
von Recklinghausenɤ˹çÊ»¤·¤¿¹ü¡¦Æð¹ü²½À¸¤òȼ¤¦Æý´â¤Î1Îã ¢¡£³·îÂ裴½µ¡§£²£¶Æü(ÅÚ¡Ë Â¾
von RecklinghausenɤËÇÙ¾®ºÙ˦´â¤ò¹çÊ»¤·¤¿1Îã ¢¡THE LUNG 12-1 ¾
Vp3´ÎºÙ˦´â¤ËÂФ·½¸³ØÅª¼£ÎŤò¹Ô¤¤Îɹ¥¤Ê·Ð²á¤ò¤¿¤É¤Ã¤Æ¤¤¤ë1Îã ¢¡´Î¡´â ¾
Vp3ºÆ¡¹È¯´ÎºÙ˦´â¤ËÂФ·¤Æ½ÑÁ°TAEÊ»ÍÑ´ÎÀÚ½ü¤Ë¤è¤ê5ǯ°Ê¾å̵ºÆÈ¯À¸Â¸¤¬ÆÀ¤é¤ì¤¿1Îã ¢¡´Î¡´â ¾
Vp4´ÎºÙ˦´â½Ñ¸åLow-Dose CDDP+5-FU´ÎưÃíÎÅË¡¤¬´ÎÆâºÆÈ¯¤ËÍ­¸ú¤Ç¤¢¤Ã¤¿1Îã ¢¡´Î¡´â ¾
VX-7°Ü¿¢Àå¼ðáç¤ËÂФ¹¤ë¼§À­Èùγ»Ò¤òÍѤ¤¤¿¼§¾ìͶƳÁÈ¿¥Æâ²¹Ç®ÎÅË¡ ¢¡15-Supplement¡¡­µ ¾
VX7°Ü¿¢Àå¼ðáç¤Î·ÛÉô¥ê¥ó¥ÑÀឰܤËÂФ¹¤ë¼§À­Èùγ»Ò¤òÍѤ¤¤¿¼§¾ìͶƳÁÈ¿¥Æâ²¹Ç®ÎÅË¡ ¢¡18-Supplement ¾
Weekly DXR/TXTÎÅË¡¤Ë¤è¤ê²þÁ±¤Î¤ß¤é¤ì¤¿Æý´â¹üž°Ü¾ÉÎã ¢¡¹üž°Ü ¾
Weekly Gemcitabine + VinorelbineÎÅË¡¤Ë¤è¤ë³°Íè²½³ØÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿ºÆÈ¯ÇÙ´â¤Î1Îã ¢¡ÇÙ´â ¾
Weekly High-Dose 5-FU(WHF)´ÎưÃíÀè¹ÔUFT+CPT-11Ê»ÍѤ¬Í­¸ú¤Ç¤¢¤Ã¤¿ÂçIJ´â¿ȯÇٴιüž°Ü¤Î1Îã ¢¡Å¾°ÜÀ­´Î¡´â ¾
Weekly Low-Dose CPT-11/CDDP³°ÍèÅêÍ¿¤¬Í­ÍѤǤ¢¤Ã¤¿5-FUÄñ¹³À­ºÆÈ¯ÂçIJ´â¤Î1Îã ¢¡·ëIJ´â ¾
Weekly Paclitaxel Regimen¤¬Â¿È¯À­Å¾°ÜÀ­Æý´â¤ËÃø¸ú¤ò¼¨¤·¤¿1¾ÉÎã ¢¡Æý´â ¾
Weekly Paclitaxel+5-FUÅêÍ¿(FTÎÅË¡)¤¬Í­ÍѤǤ¢¤Ã¤¿²«áÕ¤òȼ¤¦ÀÚ½üÉÔǽ°ß´â¤Î1Îã ¢¡°ß´â ¾
Weekly Paclitaxel¤¬Ãø¸ú¤·¤¿°ß´â¡¦Ê¢ËìÇżï¤Î1Îã ¢¡´âÀ­Ê¢Ëì±ê ¾
Weekly Paclitaxel¤È5'-DFUR¤Ë¤è¤ë½ÑÁ°²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
Weekly Paclitaxel¤È¹âÍÑÎÌToremifene¤Î¸òÂØÎÅË¡¤¬ÁÕ¸ú¤·¤¿Æý´âÇÙž°Ü¤Î1Îã ¢¡Æý´â ¾
Weekly PaclitaxelÅêÍ¿¤¬Ä¹´üÍ­ÍѤǤ¢¤ë5-Fluorouracil,Irinotecan,CisplatinÂÑÀ­¿Ê¹Ô°ß´â¤Î1Îã ¢¡ÂçIJ´â ¾
Weekly PaclitaxelÅêÍ¿¤¬Í­ÍѤǤ¢¤Ã¤¿ºÆÈ¯°ß´â¤Î1Îã ¢¡°ß´â ¾
Weekly PaclitaxelÅêÍ¿¤ÈÊü¼ÍÀþÎÅË¡¤ÎÊ»ÍѤ¬Í­ÍѤǤ¢¤Ã¤¿¿Ê¹ÔºÆÈ¯Æý´â¤Î2Îã ¢¡Æý´â ¾
Weekly PaclitaxelÅêÍ¿¤Ë¤è¤êºÆÈ¯´âÀ­Ê¢¿å¤¬´°Á´¾Ã¼º(CR)¤·¤¿ÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀឰܤòÍ­¤·¤¿StageIV°ß´â¤Î1Îã ¢¡´âÀ­Ê¢Ëì±ê ¾
Weekly PaclitaxelÅêͿˡ¤Ë¤ÆÃø¸ú¤·¤¿°ß´â´Îž°Ü¤Î1Îã ¢¡°ß´â ¾
Weekly PaclitaxelË¡¤ÇÎɹ¥¤Ê·Ð²á¤¬ÆÀ¤é¤ì¤¿½Ñ¸åºÆÈ¯ÇÙ´â¤Î1Îã ¢¡ÇÙ´â ¾
Weekly PaclitaxelÎÅË¡¤¬QOL¤Î²þÁ±¤ËÍ­¸ú¤Ç¤¢¤Ã¤¿5-FluorouracilÂÑÀ­½Ñ¸åºÆÈ¯°ß´â¤Î1Îã ¢¡°ß´â ¾
Weekly PaclitaxelÎÅˡ̵¸úÎã¤ËÂФ·Weekly Paclitaxel+5'-DFURÎÅË¡¤¬ÁÕ¸ú¤·¤¿ºÆÈ¯°ß´â¤Î1Îã ¢¡²½³ØÎÅË¡ ¾
Weekly Trastuzumab ¤ª¤è¤Ó Paclitaxel ¤¬ÁÕ¸ú¤·¤¿Æý´â´Îž°Ü¤Î1Îã ¢¡Æý´â ¾
Weekly TXT(Docetaxel)+ADM(Doxorubicin)Ê»ÍÑÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿¿Ê¹ÔºÆÈ¯Æý´â¤Î1¾ÉÎã ¢¡Æý´â ¾
WHO ʬÎà¤È¼À´µ³µÇ°¤ÎÊÑÁ«¡¡¡¦¡¦¡¦WHO ʬÎà¤Î³µÍפÈʬÎà¤ÎÊÑÁ«¡¡ WHO ʬÎà¤ÎŬÍÑ·ë²Ì¡¡ ²ò·è¤¹¤Ù¤­ÌäÂê¤Èº£¸å¤ÎŸ¡¦¡¦ ¢¡°­À­¥ê¥ó¥Ñ¼ð ¾
Wi£ìms¼ðáç¤Î¼£ÎÅ¡¡¡¦¡¦¡¦NWTS¥°¥ë¡¼¥×¥¹¥¿¥Ç¥£¤Ë¤Ä¤¤¤Æ ¡¡NWTS-1¡¡ ¡¡NWTS-2 ¡¡¡¦¡¦¡¦¡¦ ¡¦¡¦ ¢¡£´·îÂ裱½µ¡§£²Æü¡ÊÅÚ¡Ë Â¾
WS¥«¥Æ¡¼¥Æ¥ë¤òÍѤ¤¤¿´ÎưÃí²½³ØÎÅË¡¡Ý¥«¥Æ¡¼¥Æ¥ëÈ´µî¾ÉÎã¤òÃæ¿´¤Ë¡Ý ¢¡´Î¡´â ¾
XÏ¢º¿À­Ä㥬¥ó¥Þ¥°¥í¥Ö¥ê¥ó·ì¾É¤Ë¹çÊ»¤·¤¿Â¿È¯À­ÂçIJ´â¤Î1Îã39-03
Zollinger-Ellison¾É¸õ·²¤Î¿ÇÃǤȼ£ÎŤθ½¶· ¢¡¾Ã²½´ï ¾
¡ÆÃ¸¤¤¡ÇËö¾¿·¿Çٴ⡽ñ½ãXÀþÁü¤ÈCT¿ÇÃÇ¡¤ÉÂÍý¤È¤ÎÂбþ¤ò´Þ¤á¤Æ¡½ ¢¡ÇÙ´â ¾
¡È¼£¤ë¡É¤È¤¤¤¦¤³¤È¡¡¡ÝÀڤäƤ«¤é¤¬»Ï¤Þ¤ê¡¼ ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¡Ú¤Þ¤È¤á10¡ÛÁ°Î©Á£ÈîÂç¾É¤Î¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢ ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
¡Ú¤Þ¤È¤á1¡ÛƬðôÉô¼ðáç¤Î¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
¡Ú¤Þ¤È¤á2¡Û¶»¹ÐÆâ¼ðáç¤Î¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢¡¡¡¦¡¦¡¦ÇÙ´â¡¢´âÀ­¶»Ëì±ê¡¢¿©Æ»´â¡¦¡¦ ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
¡Ú¤Þ¤È¤á3¡ÛÆý´â¤È¶»Êɼðáç¤Î¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢ ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
¡Ú¤Þ¤È¤á4¡Û¾åÊ¢Éô¼ðáç¤Î¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢¡¡¡¦¡¦¡¦´ÎºÙ˦¤¬¤ó¡¢Å¾°ÜÀ­´Î¡¤¬¤ó¡¢°ß´â¡¢ÃÀÆ»´â¡¢ç¹Â¡´â¡¢¡¦¡¦ ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
¡Ú¤Þ¤È¤á5¡ÛÂçIJ´â¤Î¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
¡Ú¤Þ¤È¤á6¡ÛÉØ¿Í²Ê´â¤Î¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢¡¡¡¦¡¦¡¦»ÒµÜðô´â¡¢¡¦¡¦ ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
¡Ú¤Þ¤È¤á7¡ÛÈçÇ¢´ï²Ê´â¤Î¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢¡¡¡¦¡¦¡¦¿ÕºÙ˦´â¡¢ç¯æù´â¡¢Á°Î©Á£´â¡¢¡¦¡¦ ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
¡Ú¤Þ¤È¤á8¡ÛÆù¼ð¤Î¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
¡Ú¤Þ¤È¤á9¡Û¹ü¼ðáç¤Î¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢¡¡¡¦¡¦¡¦¸¶È¯À­¹ü¼ðá硢ž°ÜÀ­¹ü¼ðá硦¡¦ ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
£²¤Ä¤ÎÁÈ¿¥Áü¤òÍ­¤·µðÂçǹ˦¤òȼ¤¦¶½Ì£¤¢¤ë°ß GIST¡Êcommitted type¡Ë¤Î 1 Îã ¢¡GIST ¾
¤¬¤ó¤ÎInformed Consent¤ÎºÇ¶á¤ÎÊѲ½ ¢¡áÖÄË¡¦´ËÏ ¾
¤¬¤ó¤ÎÊä´°ÂåÂØ°åÎŤθ½¾õ¤ÈÌò³ä¡¡¡¦¡¦¡¦Êä´°ÂåÂØ°åÎÅ CAM ·ò¹¯¿©ÉÊ¡¡ ÌäÂêÅÀ¡¡¡¦¡¦ ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤¬¤ó°×Øí´µÀ­¤òµ¬Äꤹ¤ë°äÅÁŪ¿ÍÍÀ­¡¡¡¦¡¦¡¦°äÅÁ»Ò¿·¿¡ÊSNP):¥ª¡¼¥À¡¼¥á¥¤¥É°åÎŤؤαþÍÑ¡¦¡¦ ¢¡²½³ØÎÅË¡ ¾
¤¬¤ó²½³ØÎÅË¡¤Ë¤ª¤±¤ëÓÒµ¤¡¦ÓÒÅǤȤ½¤ÎÂкö¡¡¡¦¡¦¡¦¤¬¤ó¼£ÎŤ˱÷¤±¤ë»Ù»ýÎÅË¡¤Î°ÕµÁ ÓÒµ¤¡¦ÓÒÅÇȯ¸½¤Î¥á¥«¥Ë¥º¥à¡¡ °ø»Ò¡¡ÂнèË¡¡¡¡¦¡¦ ¢¡áÖÄË¡¦´ËÏ ¾
¤¬¤ó´µ¼Ô¤ËÂФ¹¤ëFunctional Assessment of Chronic Illness Therapy-Spiritual(FACIT-Sp)ÆüËܸìÈǤο®ÍêÀ­¡¦ÂÅÅöÀ­¤Î¸¡Æ¤(ͽÈ÷ŪĴºº)31-03
¤¬¤ó´µ¼Ô¤Î¤¿¤á¤Î¥½¡¼¥·¥ã¥ë¥ï¡¼¥¯ Ééô¤¹¤ë°åÎÅÈñ¤òÃæ¿´¤Ë- ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤¬¤ó´µ¼Ô¤Î¤¿¤á¤ÎáÖÄ˼£ÎÅÌô¤ÈÉþÌôÀâÌÀ¡¡¡¦¡¦¡¦°ìÈ̽èÊý䵤ÈËãÌô½èÊýäµ ¡¡Î²»À¥â¥ë¥Ò¥Í¡¡¥Ç¥å¥í¥Æ¥Ã¥×¥Ñ¥Ã¥Á¡¡¥ª¥­¥·¥³¥ó¥Á¥ó¡¡¥¢¥ó¥Ú¥Ã¥¯¡¦¡¦ ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤¬¤ó´µ¼Ô¤Î²ñ¤«¤é ¡Ý´µ¼Ô¦¤«¤é°å»Õ¤ËÅÁ¤¨¤¿¤¤¤³¤È ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤¬¤ó´µ¼Ô¤Î´ËÏÂ¥±¥¢ ¡Ý´ËϰåÎŤò¥È¡¼¥¿¥ë¤Ë¹Í¤¨¤ë¡Ý ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤¬¤ó´µ¼Ô¤Î¸ÆµÛº¤Æñ¤ËÂФ·¤Æ¥ª¥­¥·¥³¥É¥ó½ùÊü¾û¤¬Í­¸ú¤Ç¤¢¤Ã¤¿3¾ÉÎã ¢¡ÇÙ´â ¾
¤¬¤ó´µ¼Ô¤ÎÀº¿À¾É¾õÂкö¡¡¡¦¡¦¡¦Àº¿ÀŪ¥±¥¢¡¡¤¦¤ÄÉ¡¡¤»¤óÌÑ¡¡¡¦¡¦ ¢¡ÉûºîÍÑ Â¾
¤¬¤ó´µ¼Ô¤ÎÆñ¼£À­ÓÒÅǤËÂФ¹¤ëolanzapine¤Î»ÈÍѷи³ ¢¡ÉûºîÍÑ Â¾
¤¬¤ó´µ¼Ô¤ÎÉ԰¤ÈǺ¤ß¡¡¡Ý¤¬¤ó¼£ÎŸå¤Î´µ¼Ô¥±¥¢ ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤¬¤ó¸¡¿Ç¡¡¡¦¡¦¡¦ÆüËܤˤª¤±¤ë¸¡¿Ç¤Î¸½¾õ¤È¾­Íè¤ÎŸ˾ ±Ñ¹ñ¤Ë¤ª¤±¤ë¡¦¡¦¡¦ ÆüËܤˤª¤±¤ë´â¸¡¿Ç¤Î¸½¾õ¡¡¡¦¡¦ ¢¡´â¸¡¿Ç ¾
¤¬¤ó¸¡¿Ç¤Î¸½¾õ¤ÈÌäÂêÅÀ¡¡¡¦¡¦¡¦´â¸¡¿Ç¤ÏËÜÅö¤ËÍ­¸ú¤«¡¡ ¼õ¿Ç¤Ï½½Ê¬¤«¡¡¡¦¡¦ ¢¡´â¸¡¿Ç ¾
¤¬¤ó¸¡¿Ç¤ÎÍ­¸úÀ­É¾²Á¤È´«¹ð-²¤ÊƤθ½¾õ¤È¤ï¤¬¹ñ¤Ç¤ÎºÇ¶á¤Î¸«Ä¾¤·- ¢¡´â¸¡¿Ç ¾
¤¬¤ó¸¡¿Ç¤ÎÍ­¸úÀ­É¾²Á¤Ë´Ø¤¹¤ë¸¦µæ¡¡¡¦¡¦¡¦¹ñºÝ²ñµÄ¡¡ LeadTimeBias¡¡LengthBias¡¡ ³°¹ñ¤«¤é¸«¤¿ÆüËܤΤ¬¤ó¡¦¡¦ ¢¡´â¸¡¿Ç ¾
¤¬¤ó¸¦µæ¤Ë¤ª¤±¤ë¥È¥é¥ó¥¹¥ì¡¼¥·¥ç¥Ê¥ë¥ê¥µ¡¼¥Á ¢¡Ê¬»ÒɸŪÌô ¾
¤¬¤óºÙ˦¥Ñ¥Í¥ë¤Ë¤è¤ë²½¹çʪɾ²Á¤È¤½¤Îʬ»ÒɸŪ¥¹¥¯¥ê¡¼¥Ë¥ó¥°¤Ë¤ª¤±¤ëÌò³ä ¢¡²½³ØÎÅË¡ ¾
¤¬¤ó¼£ÎŤˤª¤±¤ëQOL¤Î°ÕµÁ¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ÉûºîÍÑ Â¾
¤¬¤ó¼£ÎŤˤª¤±¤ë´ËÏÂ¥±¥¢¥Á¡¼¥à¤ÎÌò³ä¡¡¡¦¡¦¡¦¤¬¤ó¼£ÎŤ˱÷¤±¤ë»Ù»ýÎÅË¡¤Î°ÕµÁ ´ËÏÂ¥±¥¢¥Á¡¼¥à¤È¤Ï²¿¤«¡¡¹½À®¡¡¥á¥ó¥Ð¡¼¡¡É¾²Á.. Ìò¡¦¡¦ ¢¡áÖÄË¡¦´ËÏ ¾
¤¬¤ó¼£ÎŤò½ä¤ë°åÎŷкѳء¡¡¦¡¦¡¦°åÎÅÈñ¤ÎÁýÂç¡¡ ·ÐºÑÉéô¡¡¡¦¡¦ ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤¬¤ó¼£ÎŸå¤Î´µ¼Ô¤Î¿©»ö¤È±ÉÍÜ¡¡¡¦¡¦¡¦¶ñÂÎŪ¾ã³²¤ÈÂкö°Æ¡¡ ¡¡¾ã³²Âбþ°Æ¡¡ Ç»¸üήư¿©¥Ð¥é¥ó¥¹±ÉÍܰûÎÁ¡¡ ¡¡Àº¿ÀÌ̼¸úÌÌ¡¦¡¦ ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤¬¤ó¼ê½Ñ¸å¤ÎÍÆ»ÑÊÑ·Á¤ËÂФ¹¤ë¼£ÎÅ¡¡¡¦¡¦¡¦Æ¬ðôÉôºÆ·ú¡¡ ¥¨¥Ô¥Æ¡¼¥¼¼£ÎÅ¡¡ Æý˼ºÆ·ú¡¡ ´éÌÌ¿À·ÐËãáã¡¡ Ê¢ÊÉáíº¯¥Ø¥ë¥Ë¥¢¡¦¡¦ ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤¬¤óÀ­áÖÄˤËÂФ¹¤ëÂкö¤ÈNSAIDs¡¡¡¦¡¦¡¦¥¬¥óÀ­áÖÄË¤ÎÆÃħ NSAIDs¤È¥ª¥Ô¥ª¥¤¥É¤È¤ÎÊ»ÍÑÎÅË¡ ÉûºîÍÑ¡¡»ÈÍѸ¶Â§¡¡¹ÅËì³°ÅêÍ¿¡¦¡¦ ¢¡31-1 ¾
¤¬¤óÀ­áÖÄˤνèÊý¤ÎÆÉ¤ßÊý¡¦¤È¤é¤¨Êý¡¡¡¦¡¦¡¦ÄˤߤÎɾ²Á¡¡ £×£È£ÏÊý¼°¥¬¥óáÖÄËÎÅË¡¡¡ ÌôºÞ¤Î¼ïÎà¤ÈÆÃħ¡¡¥ª¥Ô¥ª¥¤¥ÉÀ½ºÞ¡¡¥â¥ë¥Ò¥Í¡¡¡¦¡¦ ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤¬¤óÀ¸Â¸¼Ô¤Î¤¿¤á¤Î°åÎÅÊ¡»ã»ñ¸»¡¡¡¦¡¦¡¦°åÎÅÊ¡»ã»ñ¸» ¥±¥¢¡¡ ´âÀ¸Â¸¼Ô¤Î¾ã³²¤È¤Ê¤ë¤â¤Î¡¡ QOL¸þ¾å¡¡¥¬¥ó°åΞðÊó¥·¥¹¥Æ¥à¤Î¡¦¡¦ ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤¬¤óÀ¸Â¸¼Ô¤Î¼ÂÂÖ¡¡¡¦¡¦¡¦Ã»´üÀ¸Â¸¼Ô¡¡,Ĺ´üÀ¸Â¸¼Ô¡¦¡¦ ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤¬¤óÊ¢Ë잰ܤËÂФ¹¤ëCHPP¤Î¸ú²Ì¡¢¼£ÎŤμÁ¤È¸ú²Ì¤Ë¤Ä¤¤¤Æ¤Î¹Í»¡ ¢¡19-Supplement¡¡­µ ¾
¤¬¤óͽËÉ¡¡¡¦¡¦¡¦¶Ø±ìÂкö¡¡¿©À¸³è¡¡È¯´â¡¡»éËá¡ÆùÎà¡¡¾Æµû¡¡Áá´üȯ¸«¡¡¸¡¿Ç¡¦¡¦ ¢¡¿©À¸³è ¾
¤¬¤óáÖÄˤμ£ÎÅ¥¬¥¤¥É¥é¥¤¥ó¡¡¡¦¡¦¡¦¥¢¥á¥ê¥«¹ç½°¹ñ¸üÀ¸¾Ê¸ø½°±ÒÀ¸¶É·ò¹¯´ÉÍýÀ¯ºö¸¦µæµ¡´Ø¤Î²»Æ¬¼è¤ê¤Ë¤è¤ê1994ǯ¤Ë½ÐÈǤµ¤ì¤¿¡¦¡¦ ¢¡áÖÄË¡¦´ËÏ ¾
¤¬¤óáÖÄˤμ£ÎÅ¥¬¥¤¥É¥é¥¤¥ó¡¡¡¦¡¦¡¦¥¢¥á¥ê¥«¹ç½°¹ñ¸üÀ¸¾Ê¸ø½°±ÒÀ¸¶É·ò¹¯´ÉÍýÀ¯ºö¸¦µæµ¡´Ø¤Î²»Æ¬¼è¤ê¤Ë¤è¤ê1994ǯ¤Ë½ÐÈǤµ¤ì¤¿¡¦¡¦ ¢¡áÖÄË¡¦´ËÏ ¾
¤¬¤óáÖÄˤμ£ÎÅ¥¬¥¤¥É¥é¥¤¥ó¡¡¡¦¡¦¡¦¥¢¥á¥ê¥«¹ç½°¹ñ¸üÀ¸¾Ê¸ø½°±ÒÀ¸¶É·ò¹¯´ÉÍýÀ¯ºö¸¦µæµ¡´Ø¤Î²»Æ¬¼è¤ê¤Ë¤è¤ê1994ǯ¤Ë½ÐÈǤµ¤ì¤¿¡¦¡¦ ¢¡áÖÄË¡¦´ËÏ ¾
¤¬¤óáÖÄˤμ£ÎÅ¥¬¥¤¥É¥é¥¤¥ó¡¡¡¦¡¦¡¦¥¢¥á¥ê¥«¹ç½°¹ñ¸üÀ¸¾Ê¸ø½°±ÒÀ¸¶É·ò¹¯´ÉÍýÀ¯ºö¸¦µæµ¡´Ø¤Î²»Æ¬¼è¤ê¤Ë¤è¤ê1994ǯ¤Ë½ÐÈǤµ¤ì¤¿¡¦¡¦ ¢¡49-03 ¾
¤¬¤óáÖÄˤμ£ÎÅ¥¬¥¤¥É¥é¥¤¥ó¡¡¡¦¡¦¡¦¥¢¥á¥ê¥«¹ç½°¹ñ¸üÀ¸¾Ê¸ø½°±ÒÀ¸¶É·ò¹¯´ÉÍýÀ¯ºö¸¦µæµ¡´Ø¤Î²»Æ¬¼è¤ê¤Ë¤è¤ê1994ǯ¤Ë½ÐÈǤµ¤ì¤¿¡¦¡¦ ¢¡49-07 ¾
¤¬¤óáÖÄˤμ£ÎÅ¥¬¥¤¥É¥é¥¤¥ó¡¡¡¦¡¦¡¦¥¢¥á¥ê¥«¹ç½°¹ñ¸üÀ¸¾Ê¸ø½°±ÒÀ¸¶É·ò¹¯´ÉÍýÀ¯ºö¸¦µæµ¡´Ø¤Î²»Æ¬¼è¤ê¤Ë¤è¤ê1994ǯ¤Ë½ÐÈǤµ¤ì¤¿¡¦¡¦ ¢¡49-08 ¾
¤³¤ì¤«¤é¤Î´â²½³ØÎÅË¡¡¡¡¦¡¦¡¦ºÂÃ̲ñ¡¦¡¦ ¢¡²½³ØÎÅË¡ ¾
¤³¤ì¤«¤é¤ÎÆý¤¬¤ó¸¡¿Ç¡¡¡¦¡¦¡¦Æý´â¸¡¿Ç¤ÎÎò»Ë¡¡ ¡¡¸¡Æ¤²ñÃæ´ÖÊó¹ð¡¡°ø²Ì´Ø·¸¡¡ Â裲¼¡Ï·¿ÍÊÝ·òË¡¤ÈÆý´â¡¡¥Þ¥ó¥â¥°¥é¥Õ¡¦¡¦ ¢¡9·î£³½µ¡Ê£±£¶Æü¡Ë ¾
¤É¤ó¤Ê¤È¤­Ê¢¹ÐÆâ²½³ØÎÅË¡¡ÊIPÎÅË¡¡Ë¤ò¹Íθ¤¹¤Ù¤­¤« -ÍñÁ㤬¤ó ¢¡ÍñÁã´â ¾
¤Ó¤Þ¤óÀ­°­À­¶»ËìÃæÈé¼ð¤ËÂФ¹¤ë½¸³ØÅª¼£ÎÅ¡¡¡¦¡¦¡¦¾ÉÎã65ºÐ,ÃË¡¡ÀÐÌÊ ¹Í»¡¡¡¡¡cisplatin gemcitabine¡¡ ¡¡¡¦¡¦ ¢¡£¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾
¤Ó¤Þ¤óÀ­ÂçºÙ˦·¿¤Î¼£ÎÅ¡¡¡¦¡¦¡¦¿·¤·¤¤¥ê¥ó¥Ñ¼ð¤ÎʬÎप¤è¤Ó¼£ÎÅ¡¡¡¡ DLBL¤ËÂФ¹¤ë¼£ÎÅÀ®ÀӤȤȤâ¤Ë¡¢ÁØÊ̲½¼£ÎŤθ½¶·¡¦¡¦ ¢¡°­À­¥ê¥ó¥Ñ¼ð ¾
¤Þ¤ì¤Ê²èÁü½ê¸«¤òÄ褷¤¿½¼¼ÂÁ£´É´â¤Î1Îã¡¡¡¦¡¦¡¦¾ÉÎã¡¡£³£°Â塦¡¦ ¢¡8·îÂè2½µ(5Æü¡Ë ¾
¤Þ¤ì¤Ê·Ð²á,ȯ°é¤ò¼¨¤·¤¿ÃÀÆ»´â¤Î1Îã¡¡¡¦¡¦¡¦57ºÐÃËÀ­ ÃÀǹ´É´â¡¦¡¦ ¢¡£¸·î£±Æü ¾
¤è¤ê¤è¤¤°ì»þŪ²óIJ¥¹¥È¡¼¥Þ¤È¤Ï¡½¡½Ä¶Äã°ÌÁ°ÊýÀÚ½ü½Ñ¸å¥¢¥ó¥±¡¼¥ÈÄ´ºº¤«¤é ¢¡·ëIJ´â ¾
¤ï¤¬¶µ¼¼¤Ë¤ª¤±¤ë»ÒµÜ¤¬¤ó¸¡¿Ç¡¡¡¦¡¦¡¦»ÒµÜ´â¸¡¿Ç¤Î¼ÂºÝ¡¡Ìä¿Ç¡¡»ë¿Ç¡¡ºÙ˦¿Ç¡¡¥³¥ë¥Ý¥¹¥³¥Ô¡¼ »ÒµÜðôÉô°Û·ÁÀ®¤ËÂФ¹¤ë¼£ÎÅ¡¡ ¡¦¡¦ ¢¡»ÒµÜ´â ¾
¤ï¤¬¶µ¼¼¤Ë¤ª¤±¤ë»ÒµÜÂδâ¤Î´ÉÍý¡¡¡¦¡¦¡¦½ÑÁ°¸¡ºº ½Ñ¼°¤ÎÁªÂò ½Ñ¸åÊä½õÎÅË¡ ´²²òƳÆþÎÅË¡ ¼ãǯÂδâ¤Î¼è°·¤¤¡¡ ¥Õ¥©¥í¡¦¡¦ ¢¡£¸·îÂ裲½µ ¾
¤ï¤¬¶µ¼¼¤Ë¤ª¤±¤ë»ÒµÜðô´â¤Î´ÉÍý¡¡¡¦¡¦¡¦»ÒµÜðô´â½é´üÉÂÊѤδÉÍýÊý¿Ë »ÒµÜ²¹Â¸ÎÅË¡¤ÎŬ±þ ¡¦¡¦¡¦ ¿»½á´â¤ËÂФ¹¤ë´ÉÍý¡¦¡¦ ¢¡£¸·îÂè1½µ(£¶Æü¡Ë ¾
¤ï¤¬¶µ¼¼¤ÎÍñÁã¼ðáç¤Î¿ÇÃǤȼ£ÎÅ¡¡¡¦¡¦¡¦ÍñÁã¼ðá祹¥¯¥ê¡¼¥Ë¥ó¥°¡¡ ¡¡¥ê¥¹¥¯°ø»Ò¡¡·ìÀ¶¼ðáç¥Þ¡¼¥«¡¼¡¡·Ðç´Ä¶²»Çȸ¡ºº ¡¡CT/M¡¦¡¦ ¢¡9·î£²½µ¡Ê£¹Æü¡Ë ¾
¤ï¤¬¹ñ¤Ë¤ª¤±¤ë¤¬¤ó¤Î¸½¾õ ¡Ý½÷À­À­´ï¤¬¤ó¤ÎÁá´üȯ¸«¡Ý ¢¡´â¸¡¿Ç ¾
¤ï¤¬¹ñ¤Ë¤ª¤±¤ë¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢¤Î¸½¶·_·òÊݰѰ÷²ñ¤Î¥¢¥ó¥±¡¼¥ÈÊó¹ð22²ó¡¡Âç²ñ
¤ï¤¬¹ñ¤Ë¤ª¤±¤ëºßÂð±ÉÍÜÎÅË¡¤Î¸½¾õ¤ÈŸ˾¡¡¡¦¡¦¡¦ºßÂð(Ãæ¿´)ÀÅÌ®±ÉÍÜË¡ ¡¡¥¸¥ã¥±¥Ã¥È¥¿¥¤¥×.. ºßÂð·ÐIJ±ÉÍÜË¡¡¦¡¦ ¢¡¿©À¸³è ¾
¤ï¤¬¹ñ¤Ë¤ª¤±¤ë¾®»ù¸Ç·Á¼ðáç¤ÎËܳÊŪÎ×¾²¸¦µæ³ÎΩ¤Î¤¿¤á¤Î´ðÈ×À°È÷ ¢¡£´·îÂ裱½µ¡§£²Æü¡ÊÅÚ¡Ë Â¾
¤ï¤¬¹ñ¤Ë¤ª¤±¤ëÉØ¿Í²Ê°­À­¼ðáç¤ÎÈæ³ÓÎ×¾²»î¸³ ¢¡ÉØ¿Í²Ê Â¾
¤ï¤¬¹ñ¤Ë¤ª¤±¤ëʬ»ÒɸŪÌô¥²¥Õ¥£¥Á¥Ë¥Ö¤ÎÎ×¾²»î¸³ ¢¡È󾮺Ù˦´â ¾
¤ï¤¬¹ñ¤Î¤¬¤ó»à˴ư¸þ¡¡¡¦¡¦¡¦¤¬¤ó±Ö³Ø¤ÎºÇ¿·¾ðÊó¡¡¡¡¡¡¡¡ ¤Ï¤¸¤á¤Ë¡¡¡¡ ­µ.¤¬¤ó¤Ë¤è¤ë»àË´¿ô¡¡¡¡ ­¶.¤¬¤ó»à˴Ψ¡¦¡¦ ¢¡À©ÅÙ¡¦Ë¡Î§¡¦Åý·× ¾
¤ï¤¬¹ñ¤Î¤¬¤óØí´µÆ°¸þ¡¡¡¦¡¦¡¦¤¬¤ó±Ö³Ø¤ÎºÇ¿·¾ðÊó¡¡¡¡¡¡ ¤Ï¤¸¤á¤Ë¡¡¡¡ ­µ.¤ï¤¬¹ñ¤Î¤¬¤óØí´µ¿ô¡¦Î¨¤Îư¸þ¡¡¡¡ ­¶.¡¦¡¦ ¢¡À©ÅÙ¡¦Ë¡Î§¡¦Åý·× ¾
¤ï¤¬¹ñ¤ÎÊü¼ÍÀþ¼£ÎÅ¥¹¥¿¥Ã¥Õ¤È¼£Îŵ¡´ïÇÛÈ÷¾õ¶·-Êü¼ÍÀþ¼£ÎŤÎÉʼÁÊݾڤȰåÎťߥ¹ºï¸º¤Î¤¿¤á¤Ë ¢¡Êü¼ÍÀþ´ØÏ¢ ¾
¥¢¥¤¥½¥È¡¼¥×¤Ë¤è¤ëÆý´â¥»¥ó¥Á¥Í¥ë¥ê¥ó¥ÑÀáÀ¸¸¡¤ÎƳÆþ»þ¤Î·Ð°Þ¤Ë¤Ä¤¤¤Æ ¢¡¥»¥ó¥Á¥Í¥ë¥ê¥ó¥ÑÀá ¾
¥¢¥Ý¥È¡¼¥·¥¹Í¶Æ³ºÞ¤Îõº÷¡¡¡¦¡¦¡¦¹³¤¬¤óºÞõº÷¤Î¥Ð¡¼¥Á¥ã¥ë¸¦µæ½ê¡¼Ê¸Éô¾Ê¤¬¤óÆÃÄêÎΰ踦µæ¤Ë¤ª¤±¤ë¹³¤¬¤óºÞ¥¹¥¯¥ê¡¼¥Ë¥ó¥°¡¼¡¦¡¦ ¢¡²½³ØÎÅË¡ ¾
¥¢¥ë¥®¥ó»À·ÏÁϽýÈïʤºà¤òÍѤ¤¤¿êóáì 100 Îã¤Î¼£Îŷи³¡¡ ¢¡£²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾
¡¡

¥Ú¡¼¥¸¤ÎÀèÆ¬¤ËÌá¤ë¡¡¡¡ 1¡¿10¤Ø¡¡ 2¡¿10¤Ø¡¡ 3¡¿10¤Ø¡¡ 4¡¿10¤Ø¡¡ 5¡¿10¡¡ 6¡¿10¤Ø¡¡ 7¡¿10¤Ø¡¡ 8¡¿10¤Ø¡¡ 9¡¿10¤Ø¡¡ 10¡¿10¤Ø¡¡

¡¡Ãøºî¸¢Ë¡¤Î´Ø·¸¾å¡¢Í½¹ð¤Ê¤¯Ê£¼Ì¥µ¡¼¥Ó¥¹¤òÄä»ß¤·¤¿¤êÃøºî¸¢ÎÁ¤ò²þÄꤹ¤ë¾ì¹ç¤¬Í­¤ê¤Þ¤¹¡£